Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Both boards unanimously approved the all-stock merger; leadership called the combined entity 'a potent drug discovery engine poised to capitalize on…
Vertex's acquisition of Aurora (with PanVera embedded) was framed as buying an integrated discovery engine — analysts viewed the PanVera tuck-in as enhancing…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Aurora Biosciences acquired PanVera Corporation in an all-stock deal valued at ~$86M to add protein-production and high-throughput screening assay capabilities to its drug-discovery platform; Aurora (with PanVera embedded) was itself acquired by Vertex Pharmaceuticals in 2001 for ~$592M.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Aurora Biosciences Corporation / PanVera Corporation (this deal) | 2001 | $86M | — |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
← Browse all deals · How we score deals
More: 2001 deals